Associated Papers
Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
Ham JM et al.
International Journal of Molecular Sciences, 2024
Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation.
Trebino TE et al.
Elife, 2023
Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation.
Trebino T et al.
Biorxiv : the Preprint Server for Biology, 2023
Structure-Based and Knowledge-Informed Design of B-Raf Inhibitors Devoid of Deleterious PXR Binding.
Schneider M et al.
Journal of Medicinal Chemistry, 2022
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor.
Huestis MP et al.
Journal of Medicinal Chemistry, 2021
The mechanism of activation of monomeric B-Raf V600E.
Maloney RC et al.
Computational and Structural Biotechnology Journal, 2021
34188782 (PubMed )
Supplement: mmc1.docx
Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization.
Liau NPD et al.
Nature Structural & Molecular Biology, 2020
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.
Jin T et al.
Nature Communications, 2017
Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation.
Grasso M et al.
Acs Chemical Biology, 2016
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
Dhawan NS et al.
Nature, 2016
Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation.
Thevakumaran N et al.
Nature Structural & Molecular Biology, 2015
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization.
Lavoie H et al.
Nature Chemical Biology, 2013
Select a paper to view details